Skip to main content
Clinical Trials/NCT00930501
NCT00930501UnknownNot Applicable

Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients

Hadassah Medical Organization1 site in 1 country100 target enrollmentStarted: June 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
100
Locations
1
Primary Endpoint
Anti mullerian hormone

Study Overview

Brief Summary

young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.

Detailed Description

our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
5 Years to 45 Years (Child, Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • all females prior and after chemotherapy

Exclusion Criteria

  • do not consent

Outcomes

Primary Outcomes

Anti mullerian hormone

Time Frame: 2 years

Secondary Outcomes

  • inhibin b(2 years)
  • antral follicle count(2 years)
  • FSH(2 years)
  • E2 and prog(2 years)
  • menstrual history(2 years)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials